Lebrikizumab is an IgG4 monoclonal antibody against IL-13 used to treat moderate-to-severe atopic dermatitis in adults and adolescents. Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.
- Mechanism
- Curator reviewed · 1 reference
Lebrikizumab is an immunoglobulin (IgG4) monoclonal antibody that binds with high affinity to interleukin (IL)-13 and selectively inhibits IL-13 signaling through the IL-4 receptor alpha (IL-4Rα)/ IL-13 receptor alpha 1 (IL-13Rα1) heterodimer, thereby inhibiting the downstream effects of IL-13. Inhibition of IL-13 signaling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor alpha 2 (IL-13Rα2 or decoy receptor), which allows the internalization of IL-13 into the cell.
- Primary indication
- Lebrikizumab is approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.Curator reviewed · 6 structured indications
- First approval
- Canada, 2024 · United States, 2024 · European Union, 2023
- Code names
- DRM06 · LY3650150 · TNX-650
- Brand names
Resolves to
What you can answer from here — as of September 21, 2025
Which drugs share a target with Lebrikizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account